Pharmacogenomics of antibacterial and antiviral therapies: Clinical actionability, evidence gaps, and future directions.

Review of CPIC gene-drug pair clinical actionability for antibacterial and antiviral therapies

This Pharmacological Reviews review covers pharmacogenomics of anti-infective therapies — antibacterial and antiviral. It covers CPIC-actionable gene-drug pairs including HLA-B57:01/abacavir (hypersensitivity) and G6PD*/primaquine, identifying evidence gaps and future directions. A comprehensive overview for teams expanding PGx beyond oncology and cardiology.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Anti-infective PGx is often overshadowed by oncological and cardiovascular PGx, but includes some of the best-documented interactions (HLA-B57:01*/abacavir). This comprehensive Pharmacological Reviews overview provides a useful reference for preemptive genotyping programs seeking to broaden their therapeutic coverage.

Clinical impact: 3/3 · Evidence strength: 2/3 · Novelty: 0/2 · Sample size: 0/1 · Publication status: 1/1 → Total: 6/10